Alzheimer s clinical trial offering hope to patients wesh.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wesh.com Daily Mail and Mail on Sunday newspapers.
Novel antibody, TB006, demonstrated improvements in cognition and function and was well tolerated in a one-month Phase 1b/2 trial in mild to severe Alzheimer's disease (AD) patientsTB006 also demonstrated
TrueBinding Highlights the Potential of TB006’s Unique Mechanism of Action as a Novel Approach for the Treatment of Alzheimer’s Disease at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) Conference GlobeNewswire December 06, 2022 Novel antibody, TB006, demonstrated improvements in cognition and function and was well tolerated in a one-month Phase 1b/2.